Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines.

ABSTRACT: Respiratory syncytial virus (RSV) is responsible for a significant proportion of global morbidity and mortality affecting young children and older adults. In the aftermath of formalin-inactivated RSV vaccine development, the effort to develop an immunizing agent was carefully guided by epidemiologic and pathophysiological evidence of the virus, including various vaccine technologies. The pipeline of RSV vaccine development includes messenger ribonucleic acid (mRNA), live-attenuated (LAV), subunit, and recombinant vector-based vaccine candidates targeting different virus proteins. The availability of vaccine candidates of various technologies enables adjustment to the individualized needs of each vulnerable age group. Arexvy^® (GSK), followed by Abrysvo^® (Pfizer), is th

SUBMITTER: Topalidou X 

PROVIDER: S-EPMC10609699 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature